Sebati Özdemir

Sebati Özdemir

Auto-generated profile, based on publicly available information

Sebati Özdemir

Division of Gastroenterology, Department of Internal Medicine, Cerrahpaşa School of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
DEDeniz Eyice
Deniz Eyice
AKAyşe Merve Ok Kurt
Ayşe Merve Ok Kurt
ASAbdullah Sonsuz
Abdullah Sonsuz
MŞMustafa Şükrü Şenocak
Mustafa Şükrü Şenocak
MDMeliha Nur Durak
Meliha Nur Durak
AHALI IBRAHIM HATEMI
ALI IBRAHIM HATEMI
Background: Minimal hepatic encephalopathy can only be detected by specific psychometric or neuropsychological tests. We aimed to determine the prevalence of minimal hepatic encephalopathy in a hepatology outpatient clinic of a tertiary center. Methods: A total of 82 patients with chronic liver disease were involved prospectively in this study. Control groups consisted of healthy volunteers (n = 123) and chronic renal failure patients (n = 28). We used 2 different methods to detect minimal hepatic encephalopathy. First method was a battery of 5 psychometric tests (number connection tests A and B, digit symbol test, serial dot test, line tracing test) which was filled by all patients. The second method was critical flicker frequency test. Both methods were used in the whole group (n = 233). We applied linear regression analysis to the results of psychometric tests of healthy volunteers to establish equations to calculate the expected values of each test. Test results of the patients were evaluated according to the expected results obtained from these equations. Results: The prevalence of minimal hepatic encephalopathy detected by psychometric tests and critical flicker frequency test was 13% and 14%, respectively. When the positivity of both tests was deemed necessary to diagnose minimal hepatic encephalopathy, the rate of minimal hepatic encephalopathy was 3.6% (n = 3) in a chronic liver disease patient group. Conclusion: Minimal hepatic encephalopathy is a difficult clinical condition to diagnose, and it is more appropriate to use psychometric tests and critical flicker frequency test together.

15 May 2022 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
ASAbdullah Sonsuz
Abdullah Sonsuz
SBSelma Bozcan
Selma Bozcan
AHALI IBRAHIM HATEMI
ALI IBRAHIM HATEMI
SÖSebati Özdemir
Sebati Özdemir
BCBillur Canbakan
Billur Canbakan
MAMuhlis Cem Ar
Muhlis Cem Ar
Background: Hepatitis C is one of the leading causes of death in patients with inherited bleeding disorders. Currently, direct-acting antiviral drugs used for the treatment of hepatitis C have become an effective and a reliable option for people with inherited bleeding disorders. The aim of this study is to report the efficacy and safety of ombitasvir + paritaprevir/ritonavir and dasabuvir combination in the treatment of hepatitis C in patients with inherited bleeding disorders. Methods: In this retrospective study, we evaluated the efficacy and safety of the combination of ombitasvir + paritaprevir/ritonavir and dasabuvir in 10 adult patients with hemophilia A, 4 patients with hemophilia B, and 1 patient with von Willebrand disease who were infected with hepatitis C genotype 1. Results: Five patients had genotype 1a and 10 patients had genotype 1b chronic hepatitis C. One patient had Child A cirrhosis, 14 patients had chronic hepatitis C without cirrhosis. Hepatitis C virus ribonucleic acid was negative in all patients at week 4 and at the end of the treatment. Sustained virologic response was obtained in all patients. Serious side effects were detected in 3 patients, which were intra- muscular bleeding, erosive gastritis-related gastrointestinal bleeding, and pneumonia. Conclusion: Ombitasvir + paritaprevir combined with ritonavir and dasabuvir ± ribavirin is an effective treatment for patients infected with genotype 1 hepatitis C who have coagulation disorders. Tolerance and side effects are similar to other treatment options. Cite this article as: Sonsuz A, Bozcan S, Hatemi İ, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin combinations in patients with genotype 1 hepatitis C and inherited bleeding disorders. Turk J Gastroenterol. 2022;33(5):414-420.

15 June 2023 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
DEDeniz Eyice
Deniz Eyice
AKAyşe Merve Ok Kurt
Ayşe Merve Ok Kurt
ASAbdullah Sonsuz
Abdullah Sonsuz
MŞMustafa Şükrü Şenocak
Mustafa Şükrü Şenocak
MDMeliha Nur Durak
Meliha Nur Durak
AHALI IBRAHIM HATEMI
ALI IBRAHIM HATEMI
Cite this article as: Eyice D, Merve Ok A, Sonsuz A, et al. RE: Is there a more practical way for screening minimal hepatic encephalopathy? Turk J Gastroenterol. 2023;34(6):673.